The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Large Vessel Vasculitis Outcome Measures: An Update from OMERACT

Large Vessel Vasculitis Outcome Measures: An Update from OMERACT

March 19, 2019 • By Carina Stanton

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Several novel insights recently reported by the Outcome Measures in Rheumatology (OMERACT) Vasculitis Working Group get the rheumatology community closer to a core set of domains for large vessel vasculitis and will be used to establish outcome measures for use in clinical trials.1 These insights address definitions of subclinical disease activity in large vessel vasculitis and take into account patient perspectives regarding the aspects of therapy response important to them, such as pain and fatigue.2

You Might Also Like
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • New Study Aimed at Better Predicting Large Vessel Vasculitis Relapse
  • New Recommendations Guide Imaging in Large-Vessel Vasculitis
Also By This Author
  • New D.C. Office Strengthens ACR Advocacy Efforts

Clinical trials will now have validated definitions of remission, flare and patient-acceptable symptom state [PASS] to use. “The development of the definitions will provide a standardized approach—a tailored tool specifically designed for [large vessel vasculitis],” says Sibel Zehra Aydin, MD, a rheumatologist and associate professor of rheumatology at the University of Ottawa in Ontario, Canada. Dr. Aydin is the lead author of this latest OMERACT report.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Building Consensus
OMERACT is an independent initiative of international rheumatology health professionals interested in the development and validation of outcome measures in rheumatic diseases. Individual OMERACT groups hold consensus conferences every two years. The ongoing work of this OMERACT group has been to employ a data-driven approach to developing a core set of domains to shape standardized outcome measures for clinical trials of large vessel vasculitis treatments.

The comprehensive review of the literature conducted by this working group several years ago demonstrated a lack of standardized outcome measures for large vessel vasculitis.2,3 No broadly accepted definitions of important outcomes, such as disease activity or response to therapy, exist, Dr. Aydin explains. She also notes randomized controlled trials conducted for treatments targeting large vessel vasculitis diseases, such as Takayasu’s arteritis and giant cell arteritis, have usually based definitions of relapse and remission on the presence or absence of signs and symptoms and/or acute phase reactants. These measures are not consistent across studies.4

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In 2016, the OMERACT group proposed a preliminary set of core domains for use in clinical trials of large vessel vasculitis, with additional disease-specific elements, such as pain and fatigue.5 From this preliminary set of domains, the group has been working to further identify subclinical disease activity and patient perspectives for outcome measures.

Subclinical Disease Activity & Patient Outcomes
Published data and clinical advances, such as PET (positron-emission tomography), are making it easier to identify large vessel vasculitis patients who appear to be in clinical remission but who still demonstrate disease activity.5,6 This ability is leading rheumatologists to discover subcategories of large vessel vasculitis, notes Antoine Sreih, MD, a rheumatologist and assistant professor of clinical medicine at Penn Medicine in Philadelphia. Dr. Sreih specializes in caring for large vessel vasculitis patients and is a member of the OMERACT working group.6,7

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: large-vessel vasculitis, outcome, Outcome measures, Outcome Measures in Rheumatology (OMERACT), Vasculitis

You Might Also Like:
  • Infliximab, Tocilizumab Can Help in Large Vessel Vasculitis
  • New Study Aimed at Better Predicting Large Vessel Vasculitis Relapse
  • New Recommendations Guide Imaging in Large-Vessel Vasculitis
  • New Large-Vessel Vasculitis Therapies Emerge, but Better Options Still Needed

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.